23
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Targeting the Nlrp3 inflammasome as potential treatment for ethanol-induced non-communicable diseases

ORCID Icon
Pages 125-127 | Received 04 Mar 2024, Accepted 16 Mar 2024, Published online: 02 Apr 2024

References

  • Brahadeeswaran S, Dasgupta T, Manickam V, Saraswathi V, Tamizhselvi R. NLRP3: a new therapeutic target in alcoholic liver disease. Front Immunol. 2023;14:1215333. doi:10.3389/fimmu.2023.1215333. Epub 20230713 PubMed PMID: 37520548; PubMed Central PMCID: PMC10374212.
  • Cicchinelli S, Pignataro G, Gemma S, Piccioni A, Picozzi D, Ojetti V, Franceschi F, Candelli M. Pamps and DAMPs in sepsis: a review of their molecular features and potential clinical implications. Int J Mol Sci. 2024;25:962. doi:10.3390/ijms25020962. Epub 20240112, PubMed PMID: 38256033; PubMed Central PMCID: PMC10815927.
  • Liu R, Zhao B, Zhao J, Zhang M. Ethanol causes non-communicable disease through activation of NLRP3 inflammasome: a review on mechanism of action and potential interventions. Am J Drug Alcohol Abuse. 2024;1–11. doi:10.1080/00952990.2023.2297349. Epub 20240118, PubMed PMID: 38237017.
  • Crotty K, Anton P, Coleman LG, Morris NL, Lewis SA, Samuelson DR, et al. A critical review of recent knowledge of alcohol’s effects on the immunological response in different tissues. Alcohol Clin Exp Res (Hoboken). 2023;47:36–44. doi:10.1111/acer.14979. Epub 20221129, PubMed PMID: 36446606; PubMed Central PMCID: PMC9974783.
  • McMahan RH, Anton P, Coleman LG, Cresci GAM, Crews FT, Crotty KM, Luck ME, Molina PE, Vachharajani V, Weinberg J, et al. Alcohol and immunology: mechanisms of multi-organ damage. Summary of the 2022 alcohol and immunology research interest group (AIRIG) meeting. Alcohol. 2023;110:57–63. doi:10.1016/j.alcohol.2023.04.002. Epub 20230413, PubMed PMID: 37061143; PubMed Central PMCID: PMC10330898.
  • Simon L, Souza-Smith FM, Molina PE. Alcohol-associated tissue injury: current views on pathophysiological mechanisms. Annu Rev Physiol. 2022;84:87–112. PubMed PMID: 35143331. doi: 10.1146/annurev-physiol-060821-014008.
  • Wu X, Fan X, Miyata T, Kim A, Cajigas-Du Ross CK, Ray S, Huang E, Taiwo M, Arya R, Wu J, et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu Rev Pathol Mech Dis. 2023;18:411–38. doi:10.1146/annurev-pathmechdis-031521-030435. Epub 20221021, PubMed PMID: 36270295; PubMed Central PMCID: PMC10060166.
  • Kane CJ, Phelan KD, Han L, Smith RR, Xie J, Douglas JC, Drew PD. Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists. Brain Behav Immun. 2011;25:S137–45. doi:10.1016/j.bbi.2011.02.016. Epub 20110303, PubMed PMID: 21376806; PubMed Central PMCID: PMC3104506.
  • Niedzwiedz-Massey VM, Douglas JC, Rafferty T, Johnson JW, Holloway KN, Berquist MD, et al. Risk, resilience, and thriving among racial/ethnic minorities and underserved populations at-risk for substance use disorders. Am J Drug Alcohol Abuse. 2022;48:1–14. doi:10.1080/00952990.2022.2128361. Epub 2022/11/09, PubMed PMID: 36345683.
  • Pascual M, Montesinos J, Guerri C. Role of the innate immune system in the neuropathological consequences induced by adolescent binge drinking. J Neurosci Res. 2018;96:765–80. doi:10.1002/jnr.24203. Epub 20171207, PubMed PMID: 29214654.
  • Crews FT, Coleman LG Jr., Macht VA, Vetreno RP, Dantzer R. Targeting persistent changes in neuroimmune and epigenetic signaling in adolescent drinking to treat alcohol use disorder in adulthood. Pharmacol Rev. 2023;75:380–96. doi:10.1124/pharmrev.122.000710. Epub 20221212, PubMed PMID: 36781218; PubMed Central PMCID: PMC9969522.
  • Crews FT, Qin L, Sheedy D, Vetreno RP, Zou J. High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence. Biol Psychiatry. 2013;73:602–12. doi:10.1016/j.biopsych.2012.09.030. Epub 2012/12/05, PubMed PMID: 23206318; PubMed Central PMCID: PMC3602398.
  • Szabo G, Lippai D. Converging actions of alcohol on liver and brain immune signaling. Int Rev Neurobiol. 2014;118:359–80. doi:10.1016/B978-0-12-801284-0.00011-7. PubMed PMID: 25175869.
  • Ono Y, Maejima Y, Saito M, Sakamoto K, Horita S, Shimomura K, Inoue S, Kotani J. TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice. Sci Rep. 2020;10:694. doi:10.1038/s41598-020-57714-3. Epub 20200120, PubMed PMID: 31959927; PubMed Central PMCID: PMC6970997.
  • Xie B, Wang B, Shang R, Wang L, Huang X, Xie L. Blocking MyD88 signaling with MyD88 inhibitor prevents colitis-associated colorectal cancer development by maintaining colonic microbiota homeostasis. Sci Rep. 2023;13:22552. doi:10.1038/s41598-023-49457-8. Epub 20231218, PubMed PMID: 38110638; PubMed Central PMCID: PMC10728211.
  • El-Sharkawy LY, Brough D, Freeman S. Inhibiting the NLRP3 Inflammasome. Molecules. 2020;25:5533. doi:10.3390/molecules25235533. Epub 20201125, PubMed PMID: 33255820; PubMed Central PMCID: PMC7728307.
  • Le Dare B, Ferron PJ, Gicquel T. The purinergic P2X7 receptor-NLRP3 inflammasome pathway: a new target in alcoholic liver disease? Int J Mol Sci. 2021;22:2139. doi: 10.3390/ijms22042139. Epub 20210221, PubMed PMID: 33670021; PubMed Central PMCID: PMC7926651.
  • Zheng H, Liu Q, Zhou S, Luo H, Zhang W. Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases. Front Immunol. 2024;15:1345625. doi:10.3389/fimmu.2024.1345625. Epub 20240202, PubMed PMID: 38370420; PubMed Central PMCID: PMC10869479.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.